

## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address, COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/883,848	06/18/2001	Leona E. Ling	CIBT-P01-119		
28120 7	7590 01/13/2003				
ROPES & GRAY			EXAMINER		
	ATIONAL PLACE 02110-2624	•	YAEN, CHRISTOPHER H		
			ART UNIT	PAPER NUMBER	
			1642	1.0	
			DATE MAILED: 01/13/2003	12	

Please find below and/or attached an Office communication concerning this application or proceeding.

	<del>_</del>			Applicatio	n No.	Applicant(s)				
				09/883,84	8	LING ET AL.				
	Offic	Action Summary		Examiner	,	Art Unit	_			
				Christophe	r H Yaen	1642				
	The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply									
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).  - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).  Status										
1)⊠	Respons	ive to communication(s)	filed on 29 O	ctober 200	<u>2</u> .					
2a)[_	This action	on is <b>FINAL</b> .	2b)⊠ This	s action is i	non-final.		r			
3)										
	on of Clai	•	- 11 41							
• —	4)⊠ Claim(s) <u>1-35</u> is/are pending in the application.									
	4a) Of the above claim(s) is/are withdrawn from consideration.									
5) Claim(s) is/are allowed.										
<u> </u>	6) ☐ Claim(s) is/are rejected. 7) ☐ Claim(s) is/are objected to.									
<u> </u>	` ' -	-35 are subject to restric	rtion and/or e	lection real	irement					
<i>,</i> —	on Papers		non and/or e	ection requ						
	_	cation is objected to by t	the Examiner	•						
10) 🔲 -	The drawin	g(s) filed on is/ar	e: a)∏ accept	ted or b)☐ d	objected to by the Exar	miner.				
	Applicant	may not request that any o	bjection to the	drawing(s)	be held in abeyance. Se	ee 37 CFR 1.85(a).				
11) 🔲 -	The propos	sed drawing correction fil	ed on	is: a)□ ap	proved b) disappro	ved by the Examin	er.			
If approved, corrected drawings are required in reply to this Office action.										
12) The oath or declaration is objected to by the Examiner.										
Priority u	ınder 35 U	.S.C. §§ 119 and 120								
13)	Acknowled	dgment is made of a clai	m for foreign	priority und	der 35 U.S.C. § 119(a	)-(d) or (f).				
a)[	All b)[_	] Some * c)☐ None of	:							
	1. Certified copies of the priority documents have been received.									
	2. Cer	tified copies of the priori	y documents	have beer	received in Application	on No				
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).  * See the attached detailed Office action for a list of the certified copies not received.										
14) 🗌 A	cknowledg	ment is made of a claim	for domestic	priority un	der 35 U.S.C. § 119(e	) (to a provisiona	l application).			
		anslation of the foreign la gment is made of a claim								
Attachmen	t(s)			•						
2) Notic	e of Draftspe	es Cited (PTO-892) rson's Patent Drawing Review sure Statement(s) (PTO-1449)	,		'= '	(PTO-413) Paper No Patent Application (PT	· /			

Application/Control Number: 09/883,848 Page 2

Art Unit: 1642

## **DETAILED ACTION**

1. The amendment filed 10/29/2002 (paper no. 11) is acknowledged. Upon further review and reconsideration, the previous office action is vacated in view of the following new restriction/election requirement.

## Election/Restrictions

- 2. Restriction to one of the following inventions is required under 35 U.S.C. 121:
  - I. Claims 1-17, and 25-27 drawn to a method of promoting angiogenesis in a subject comprising administering an angiogenic amount of a hedgehog polypeptide or agonsit thereof, classified in class 514, subclass 2.
  - II. Claims 28-29, drawn to a method of promoting angiogenesis in a subject comprising administering an angiogenic amount of a hedgehog nucleic acid molecule, classified in class 536, subclass 23.1.
  - III. Claims 18-24 and 30-34, drawn to a method of inhibiting angiogenesis comprising the administration of an antiangiogenic amount of hedgehog antagonist, classified in class 514, subclass 2.

The inventions are distinct, each from the other because of the following reasons:

- 3. The inventions differ one from the other because the inventions are drawn to methodologically different procedures which require different reagents, different protocols and have different purposes and are used for different reasons.
- 4. Because these inventions are distinct for the reasons given above and the search required for Groups I-III are not required for one for the other, restriction for examination purposes as indicated is proper.

Application/Control Number: 09/883,848

Art Unit: 1642

5. This application contains claims directed to the following patentably distinct species of the claimed invention:

- a. If the applicant elects group I, please select **one** from each of the following groups (i-iv):
  - i. SEQ ID No: 10-18, or 20 (claim 4), 1-9 or 19 (claim 5), PLEASE SELECT ONE SEQUENCE FOR EXAMINATION;
  - ii. Chemical moieties: polyalkylene glycol polymer (claim 9), phosphate groups (claim 12), acetyl groups (claim13), sugar or carbohydrate groups (claim 14);
  - iii. Agent (claim 17): VEGF, HGF, bFGF, angiopoietin-1, angiopoietin-2, MCP-1;
  - iv. Formula XII: applicant must select one specific Ar, Ar', Y, X, M, R, Cy, Cy', i, and n.
- b. If the applicant elects group III, please select one of the following formulas: I-XI, wherein if the applicant elects formula I, applicant must select one specific R1, R2, L, X1, X2, Y1, Y2, Z1, Z2, R8, p, and n; wherein if applicant elects formula VI, applicant must select one specific R1, R2, R3, R4, L, X, D, Y, Z, E, R8, p, n, q, and r.

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, claims 4,5,9,12,13,14,17,27,32,33, and 34 are generic.

Application/Control Number: 09/883,848

Art Unit: 1642

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

- 6. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).
- 7. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Application/Control Number: 09/883,848 Page 5

Art Unit: 1642

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Christopher H Yaen whose telephone number is 703-305-3586. The examiner can normally be reached on Monday-Friday 9-5.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Anthony Caputa can be reached on 703-308-3995. The fax phone numbers for the organization where this application or proceeding is assigned are 703-308-4242 for regular communications and 703-305-3014 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0196.

Christopher Yaen Art Unit 1642 January 13, 2003

ANTHONY C. CAPUTA
SUPERVISORY PATERIX TYPES
TECHNOLOGY CENTER 1600